You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMannitol
Accession NumberDB00742  (APRD01083, EXPT02246)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid.
Structure
Thumb
Synonyms
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
D-(-)-Mannitol
D-Mannitol
e 421
e-421
e421
Fraxinine
Manitol
Manna Sugar
Mannit
Mannite
Mannitol
Mannitolum
Osmitrol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BronchitolInhalation powder, hard capsule40 mgInhalation usePharmaxis Pharmaceuticals Limited2012-04-13Not applicableEu
BronchitolInhalation powder, hard capsule40 mgInhalation usePharmaxis Pharmaceuticals Limited2012-04-13Not applicableEu
Mannitolinjection, solution5 g/100mLintravenousHospira, Inc.1987-01-08Not applicableUs
Mannitolirrigant5 g/100mLirrigationB. Braun Medical Inc.1978-02-10Not applicableUs
Mannitolinjection, solution10 g/100mLintravenousHospira, Inc.1987-01-08Not applicableUs
Mannitolinjection, solution20 g/100mLintravenousB. Braun Medical Inc.1993-07-26Not applicableUs
Mannitolinjection, solution15 g/100mLintravenousHospira, Inc.1987-01-08Not applicableUs
Mannitolinjection, solution12.5 g/50mLintravenousHospira, Inc.1967-12-22Not applicableUs
Mannitolinjection, solution20 g/100mLintravenousHospira, Inc.1987-01-08Not applicableUs
Mannitol 20%solution200 mgintravenousHospira Healthcare Corporation1963-12-31Not applicableCanada
Mannitol 25%solution250 mgintravenousHospira Healthcare Corporation1970-12-31Not applicableCanada
Mannitol Inj 10% Abbovacliquid100 mgintravenousAbbott Laboratories, Limited1963-12-311999-08-09Canada
Mannitol Inj 25%liquid250 mgintravenousAstra Pharma Inc.1987-12-312000-07-20Canada
Mannitol Inj 25%liquid250 mgintravenousInternational Medication Systems Ltd.1971-12-311997-08-15Canada
Mannitol Inj 5% Abbovacliquid50 mgintravenousAbbott Laboratories, Limited1963-12-311999-08-09Canada
Mannitol Injectionsolution250 mgintravenousFresenius Kabi Canada Ltd2002-04-09Not applicableCanada
Osmitrolinjection, solution15 g/100mLintravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
Osmitrolinjection, solution20 g/100mLintravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
Osmitrolinjection, solution5 g/100mLintravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
Osmitrolinjection, solution10 g/100mLintravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
Osmitrol 10% Inj USPliquid10 gintravenousBaxter Corporation1989-12-31Not applicableCanada
Osmitrol 20% Inj USPsolution20 gintravenousBaxter Corporation1989-12-31Not applicableCanada
Resectisol (5% Mannitol Irrigation)liquid5 %irrigationB. Braun Medical Inc1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mannitolinjection, solution250 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Mannitolinjection, solution250 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Mannitolinjection, solution12.5 g/50mLintravenousCardinal Health2010-02-01Not applicableUs
Mannitolinjection, solution250 mg/mLintravenousFresenius Kabi USA, LLC2000-03-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnolAstar
AridolPharmaxis
BronchitolPharmaxis
DeltamannitDeltaSelect
DemanitolMedifarma
DiurecideLusa
IsotolNot Available
ManicolNot Available
ManitPliva
Manitol MeinFresenius
ManitonNot Available
MannigenNot Available
MannisolHuman Co. Ltd.
Mannisol ATeva
MannitNot Available
Mannit-LösungSerag-Wiessner
Mannite ActipharmActipharm
OsmofundinB. Braun
OsmohalePharmaxis
OsmosolBeximco
OsmosterilFresenius
ResectisolB. Braun
Brand mixtures
NameLabellerIngredients
Additive Solution Sodium Adenine Glucose Mannitol (sagm)Maco Pharma
Cystosol W 3% HexitolsBaxter Corporation
Leukosep - Solx A Additive SolutionHaemonetics Manufacturing Inc
Leukotrap Solx A AdditiveHaemonetics Manufacturing Inc
Sag-MHaemonetics Corporation
Sorbitol Mannitol IrrigationHospira Healthcare Corporation
Sorbitol-mannitolHospira, Inc.
SaltsNot Available
Categories
UNII3OWL53L36A
CAS number69-65-8
WeightAverage: 182.1718
Monoisotopic: 182.07903818
Chemical FormulaC6H14O6
InChI KeyInChIKey=FBPFZTCFMRRESA-KVTDHHQDSA-N
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
IUPAC Name
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
SMILES
OC[C@@H](O)[C@@H](O)[[email protected]](O)[[email protected]](O)CO
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassSugar alcohols
Direct ParentSugar alcohols
Alternative Parents
Substituents
  • Sugar alcohol
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Hydrocarbon derivative
  • Primary alcohol
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationUsed for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.
PharmacodynamicsChemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.
Mechanism of actionMannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).
Related Articles
AbsorptionApproximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.
Volume of distributionNot Available
Protein bindingNone
Metabolism

Mannitol is metabolized only slightly, if at all, to glycogen in the liver.

SubstrateEnzymesProduct
Mannitol
Not Available
GlycogenDetails
Route of eliminationIt is rapidly excreted in the urine.
Half life100 minutes
ClearanceNot Available
ToxicityLD50=1700 mg/kg (rat oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6525
Blood Brain Barrier-0.5997
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.662
P-glycoprotein inhibitor INon-inhibitor0.9535
P-glycoprotein inhibitor IINon-inhibitor0.9551
Renal organic cation transporterNon-inhibitor0.9252
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.878
CYP450 3A4 substrateNon-substrate0.7431
CYP450 1A2 substrateNon-inhibitor0.824
CYP450 2C9 inhibitorNon-inhibitor0.9419
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9232
CYP450 3A4 inhibitorNon-inhibitor0.9402
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.958
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7823
BiodegradationReady biodegradable0.8595
Rat acute toxicity1.1260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.9329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • B braun medical inc
  • Hospira inc
  • Miles laboratories inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • International medication system
  • Luitpold pharmaceuticals inc
  • Merck and co inc
  • Watson laboratories inc
  • Baxter healthcare corp
Packagers
Dosage forms
FormRouteStrength
Inhalation powder, hard capsuleInhalation use40 mg
Liquidirrigation
Solutionintravenous
Injection, solutionintravenous12.5 g/50mL
Injection, solutionintravenous20 g/100mL
Injection, solutionintravenous250 mg/mL
Irrigantirrigation5 g/100mL
Solutionintravenous200 mg
Solutionintravenous250 mg
Liquidintravenous100 mg
Liquidintravenous250 mg
Liquidintravenous50 mg
Injection, solutionintravenous10 g/100mL
Injection, solutionintravenous15 g/100mL
Injection, solutionintravenous5 g/100mL
Liquidintravenous10 g
Solutionintravenous20 g
Liquidirrigation5 %
Solution0-unassigned
Solutionirrigation
Irriganturethral
Prices
Unit descriptionCostUnit
Osmitrol 20% iv solution0.15USD ml
Osmitrol 10% iv solution0.07USD ml
Osmitrol 15% iv solution0.07USD ml
Mannitol powder0.05USD g
Mannitol 15% iv solution0.04USD ml
Mannitol 20% iv solution0.04USD ml
Mannitol 25% vial0.03USD ml
Osmitrol 5% iv solution0.03USD ml
Mannitol 10% iv solution0.02USD ml
Mannitol 5% iv solution0.02USD ml
Resectisol 5% solution0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168 °CPhysProp
boiling point290-295 °C at 3.50E+00 mm HgPhysProp
water solubility2.16E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-3.10HANSCH,C ET AL. (1995)
Caco2 permeability-6.21ADME Research, USCD
pKa13.5 (at 25 °C)BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility229.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-3.7ChemAxon
logS0.1ALOGPS
pKa (Strongest Acidic)12.59ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area121.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity38.4 m3·mol-1ChemAxon
Polarizability16.82 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.14 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (6 TMS)splash10-0ktb-0931000000-b481d576c5f24dd1b1d5View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-066s-0942000000-20043a375d72ca08dce9View in MoNA
GC-MSGC-MS Spectrum - GC-MS (6 TMS)splash10-066r-1974000000-38a4beaca17ab8c750b6View in MoNA
GC-MSGC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-014j-9600000000-26f4335f7ef7c81ca261View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-066r-9000000000-73db1fbd51fb8c061becView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-05mo-9000000000-45a4dea1d21286c4b8daView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-0089-6900000000-961d76d6550bc342ffa1View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Walter M. Kruse, “Process for preparing mannitol from glucose.” U.S. Patent US4029878, issued August, 1956.

US4029878
General References
  1. Cruz J, Minoja G, Okuchi K: Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: a randomized trial. Neurosurgery. 2001 Oct;49(4):864-71. [PubMed:11564247 ]
  2. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery. 2002 Sep;51(3):628-37; discussion 637-8. [PubMed:12188940 ]
  3. Cruz J, Minoja G, Okuchi K, Facco E: Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004 Mar;100(3):376-83. [PubMed:15035271 ]
  4. Roberts I, Smith R, Evans S: Doubts over head injury studies. BMJ. 2007 Feb 24;334(7590):392-4. [PubMed:17322250 ]
  5. Wakai A, Roberts I, Schierhout G: Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001049. [PubMed:16235278 ]
  6. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187 ]
External Links
ATC CodesB05CX04B05BC01A06AD16R05CB16
AHFS Codes
  • 36:68.00
  • 40:28.12
  • 40:36.00
PDB Entries
FDA labelDownload (50 KB)
MSDSDownload (72.1 KB)
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.
AcetaminophenThe serum concentration of Mannitol can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Acetazolamide.
AfatinibThe serum concentration of Mannitol can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Mannitol can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.
AldosteroneThe serum concentration of Mannitol can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Mannitol can be increased when it is combined with Alectinib.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mannitol.
AliskirenThe risk or severity of adverse effects can be increased when Mannitol is combined with Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Mannitol.
AmantadineThe serum concentration of Mannitol can be increased when it is combined with Amantadine.
AmikacinMannitol may increase the nephrotoxic activities of Amikacin.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mannitol.
Aminohippuric acidThe serum concentration of Mannitol can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Mannitol can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Mannitol can be increased when it is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol.
AmobarbitalAmobarbital may increase the hypotensive activities of Mannitol.
AmprenavirThe serum concentration of Mannitol can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Mannitol can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Mannitol is combined with Amyl Nitrite.
ApraclonidineThe risk or severity of adverse effects can be increased when Mannitol is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Mannitol.
AstemizoleThe serum concentration of Mannitol can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Mannitol can be increased when it is combined with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Mannitol.
AtorvastatinThe serum concentration of Mannitol can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Mannitol can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Mannitol is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Mannitol can be increased when it is combined with Azithromycin.
BarbitalBarbital may increase the hypotensive activities of Mannitol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.
BenzocaineThe serum concentration of Mannitol can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Mannitol can be increased when it is combined with Bepridil.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Mannitol.
BiperidenThe serum concentration of Mannitol can be increased when it is combined with Biperiden.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mannitol.
BosutinibThe serum concentration of Mannitol can be increased when it is combined with Bosutinib.
BretyliumThe risk or severity of adverse effects can be increased when Mannitol is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mannitol.
BromocriptineThe serum concentration of Mannitol can be increased when it is combined with Bromocriptine.
BumetanideThe risk or severity of adverse effects can be increased when Mannitol is combined with Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol.
BuspironeThe serum concentration of Mannitol can be increased when it is combined with Buspirone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mannitol.
CabazitaxelThe serum concentration of Mannitol can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Mannitol can be increased when it is combined with Caffeine.
CanagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Candesartan.
CaptoprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.
CarbamazepineThe serum concentration of Mannitol can be decreased when it is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Mannitol.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Mannitol.
CarvedilolThe risk or severity of adverse effects can be increased when Mannitol is combined with Carvedilol.
CaspofunginThe serum concentration of Mannitol can be increased when it is combined with Caspofungin.
ChloroquineThe serum concentration of Mannitol can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.
ChlorpromazineThe serum concentration of Mannitol can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Mannitol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Mannitol can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mannitol.
CholesterolThe serum concentration of Mannitol can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Mannitol can be decreased when it is combined with Cholic Acid.
CilazaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.
CimetidineThe serum concentration of Mannitol can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Mannitol can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Mannitol can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Mannitol can be increased when it is combined with Clarithromycin.
ClevidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.
ClofazimineThe serum concentration of Mannitol can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Mannitol can be increased when it is combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.
ClotrimazoleThe serum concentration of Mannitol can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Mannitol can be increased when it is combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mannitol.
ColchicineThe serum concentration of Mannitol can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Mannitol can be increased when it is combined with Colforsin.
CrizotinibThe serum concentration of Mannitol can be increased when it is combined with Crizotinib.
CyclophosphamideThe serum concentration of Mannitol can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Mannitol can be decreased when it is combined with Cyclosporine.
DaclatasvirThe serum concentration of Mannitol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Mannitol can be increased when it is combined with Dactinomycin.
DapagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.
DasatinibThe serum concentration of Mannitol can be increased when it is combined with Dasatinib.
DaunorubicinMannitol may increase the nephrotoxic activities of Daunorubicin.
DaunorubicinThe serum concentration of Mannitol can be decreased when it is combined with Daunorubicin.
DesipramineThe serum concentration of Mannitol can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Mannitol can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Mannitol can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mannitol.
DextromethorphanThe serum concentration of Mannitol can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mannitol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mannitol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Mannitol.
DiclofenacThe serum concentration of Mannitol can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Diclofenamide.
DigoxinThe serum concentration of Mannitol can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mannitol.
DihydroergotamineThe serum concentration of Mannitol can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mannitol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mannitol.
DihydrostreptomycinMannitol may increase the nephrotoxic activities of Dihydrostreptomycin.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Mannitol.
DinutuximabThe risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mannitol.
DipyridamoleThe risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.
DoxepinThe serum concentration of Mannitol can be increased when it is combined with Doxepin.
DoxorubicinMannitol may increase the nephrotoxic activities of Doxorubicin.
DoxorubicinThe serum concentration of Mannitol can be decreased when it is combined with Doxorubicin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Mannitol.
DronabinolThe serum concentration of Mannitol can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Mannitol can be increased when it is combined with Dronedarone.
DuloxetineMannitol may increase the orthostatic hypotensive activities of Duloxetine.
ElbasvirThe serum concentration of Mannitol can be increased when it is combined with Elbasvir.
EmpagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.
EnzalutamideThe serum concentration of Mannitol can be increased when it is combined with Enzalutamide.
EpirubicinMannitol may increase the nephrotoxic activities of Epirubicin.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Mannitol.
EprosartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.
ErgonovineThe serum concentration of Mannitol can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Mannitol can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Mannitol can be decreased when it is combined with Erythromycin.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Mannitol.
EstramustineThe serum concentration of Mannitol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Mannitol can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Mannitol can be decreased when it is combined with Estrone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Mannitol is combined with Etacrynic acid.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mannitol.
EtoposideThe serum concentration of Mannitol can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mannitol.
EtravirineThe serum concentration of Mannitol can be increased when it is combined with Etravirine.
FelodipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mannitol.
FexofenadineThe serum concentration of Mannitol can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Mannitol can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Mannitol can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Mannitol can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Mannitol can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Mannitol can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Mannitol can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Mannitol can be increased when it is combined with Fluvoxamine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.
FramycetinMannitol may increase the nephrotoxic activities of Framycetin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mannitol.
GefitinibThe serum concentration of Mannitol can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Mannitol can be increased when it is combined with Genistein.
GentamicinMannitol may increase the nephrotoxic activities of Gentamicin.
GlyburideThe serum concentration of Mannitol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Mannitol can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Mannitol can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Mannitol can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Mannitol is combined with Guanfacine.
HaloperidolThe serum concentration of Mannitol can be increased when it is combined with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Mannitol.
HexobarbitalHexobarbital may increase the hypotensive activities of Mannitol.
HydralazineThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mannitol.
HydrocortisoneThe serum concentration of Mannitol can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol.
Hygromycin BMannitol may increase the nephrotoxic activities of Hygromycin B.
IdarubicinMannitol may increase the nephrotoxic activities of Idarubicin.
IdelalisibThe serum concentration of Mannitol can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Mannitol can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Mannitol can be increased when it is combined with Imipramine.
IndapamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Indapamide.
IndinavirThe serum concentration of Mannitol can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Mannitol can be increased when it is combined with Indomethacin.
IrbesartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.
IsavuconazoniumThe serum concentration of Mannitol can be increased when it is combined with Isavuconazonium.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Mannitol is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Mannitol.
ItraconazoleThe serum concentration of Mannitol can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Mannitol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Mannitol can be increased when it is combined with Ivermectin.
KanamycinMannitol may increase the nephrotoxic activities of Kanamycin.
KetamineThe serum concentration of Mannitol can be increased when it is combined with Ketamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mannitol.
KetoconazoleThe serum concentration of Mannitol can be increased when it is combined with Ketoconazole.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.
LansoprazoleThe serum concentration of Mannitol can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Mannitol can be increased when it is combined with Lapatinib.
LevobunololThe risk or severity of adverse effects can be increased when Mannitol is combined with Levobunolol.
LevodopaMannitol may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Mannitol can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mannitol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mannitol.
LevothyroxineThe serum concentration of Mannitol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Mannitol can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Mannitol can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Mannitol can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Mannitol.
LomitapideThe serum concentration of Mannitol can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Mannitol can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Mannitol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Mannitol can be increased when it is combined with Loratadine.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.
LovastatinThe serum concentration of Mannitol can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Mannitol can be decreased when it is combined with Lumacaftor.
MaprotilineThe serum concentration of Mannitol can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Mannitol can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.
MefloquineThe serum concentration of Mannitol can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Mannitol can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Mannitol can be increased when it is combined with Meprobamate.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mannitol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Mannitol.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Mannitol.
MethohexitalMethohexital may increase the hypotensive activities of Mannitol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.
MethyldopaThe risk or severity of adverse effects can be increased when Mannitol is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Mannitol.
MetipranololThe risk or severity of adverse effects can be increased when Mannitol is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mannitol.
MetrizamideMannitol may increase the nephrotoxic activities of Metrizamide.
MibefradilThe serum concentration of Mannitol can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Mannitol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Mannitol can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Mannitol can be decreased when it is combined with Mifepristone.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mannitol.
MitomycinThe serum concentration of Mannitol can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Mannitol can be decreased when it is combined with Mitoxantrone.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mannitol.
NadololThe risk or severity of adverse effects can be increased when Mannitol is combined with Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mannitol.
NaltrexoneThe serum concentration of Mannitol can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Mannitol can be increased when it is combined with Naringenin.
NebivololThe risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.
NefazodoneThe serum concentration of Mannitol can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Mannitol can be decreased when it is combined with Nelfinavir.
NeomycinMannitol may increase the nephrotoxic activities of Neomycin.
NeostigmineThe serum concentration of Mannitol can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Mannitol is combined with Nesiritide.
NetilmicinMannitol may increase the nephrotoxic activities of Netilmicin.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.
NicorandilNicorandil may increase the hypotensive activities of Mannitol.
NifedipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Nifedipine.
NilotinibThe serum concentration of Mannitol can be increased when it is combined with Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mannitol.
NitrazepamThe serum concentration of Mannitol can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Mannitol can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Mannitol.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mannitol.
NorethisteroneThe serum concentration of Mannitol can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Mannitol.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mannitol.
OmeprazoleThe serum concentration of Mannitol can be increased when it is combined with Omeprazole.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Mannitol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mannitol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mannitol.
P-NitrophenolThe serum concentration of Mannitol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Mannitol can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Mannitol can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Mannitol can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.
ParomomycinMannitol may increase the nephrotoxic activities of Paromomycin.
ParoxetineThe serum concentration of Mannitol can be increased when it is combined with Paroxetine.
PenbutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.
PentobarbitalPentobarbital may increase the hypotensive activities of Mannitol.
PerindoprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mannitol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Mannitol.
PimozideThe serum concentration of Mannitol can be increased when it is combined with Pimozide.
PindololThe risk or severity of adverse effects can be increased when Mannitol is combined with Pindolol.
Platelet Activating FactorThe serum concentration of Mannitol can be decreased when it is combined with Platelet Activating Factor.
PlicamycinMannitol may increase the nephrotoxic activities of Plicamycin.
PonatinibThe serum concentration of Mannitol can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Mannitol can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Mannitol can be increased when it is combined with Pravastatin.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.
PrednisoneThe serum concentration of Mannitol can be increased when it is combined with Prednisone.
PrimidonePrimidone may increase the hypotensive activities of Mannitol.
ProbenecidThe serum concentration of Mannitol can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Mannitol can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Mannitol can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Mannitol can be increased when it is combined with Propafenone.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol.
ProtriptylineThe serum concentration of Mannitol can be increased when it is combined with Protriptyline.
PuromycinMannitol may increase the nephrotoxic activities of Puromycin.
QuercetinThe serum concentration of Mannitol can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.
QuinacrineThe serum concentration of Mannitol can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.
QuinidineThe serum concentration of Mannitol can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Mannitol can be increased when it is combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mannitol.
RanitidineThe serum concentration of Mannitol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Mannitol can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Mannitol can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Mannitol can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mannitol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mannitol.
RibostamycinMannitol may increase the nephrotoxic activities of Ribostamycin.
RifampicinThe serum concentration of Mannitol can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Mannitol can be increased when it is combined with Rilpivirine.
RiociguatThe risk or severity of adverse effects can be increased when Mannitol is combined with Riociguat.
RisperidoneMannitol may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Mannitol can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Mannitol can be increased when it is combined with Rolapitant.
SaquinavirThe serum concentration of Mannitol can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Mannitol can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Mannitol.
SelegilineThe serum concentration of Mannitol can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Mannitol can be increased when it is combined with Sertraline.
SimeprevirThe serum concentration of Mannitol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Mannitol can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Mannitol can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Mannitol can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.
SpectinomycinMannitol may increase the nephrotoxic activities of Spectinomycin.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.
St. John's WortThe serum concentration of Mannitol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Mannitol can be increased when it is combined with Staurosporine.
StreptomycinMannitol may increase the nephrotoxic activities of Streptomycin.
StreptozocinMannitol may increase the nephrotoxic activities of Streptozocin.
StreptozocinThe serum concentration of Mannitol can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.
SulfinpyrazoneThe serum concentration of Mannitol can be increased when it is combined with Sulfinpyrazone.
SumatriptanThe serum concentration of Mannitol can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Mannitol can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Mannitol can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Mannitol can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Mannitol can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mannitol.
Taurocholic AcidThe serum concentration of Mannitol can be increased when it is combined with Taurocholic Acid.
TelmisartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.
TemsirolimusThe serum concentration of Mannitol can be increased when it is combined with Temsirolimus.
TerazosinThe risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.
TerfenadineThe serum concentration of Mannitol can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Mannitol can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Mannitol can be increased when it is combined with Testosterone.
ThiamylalThiamylal may increase the hypotensive activities of Mannitol.
ThiopentalThiopental may increase the hypotensive activities of Mannitol.
TicagrelorThe serum concentration of Mannitol can be increased when it is combined with Ticagrelor.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Mannitol.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.
TobramycinMannitol may increase the nephrotoxic activities of Tobramycin.
TolvaptanThe serum concentration of Mannitol can be increased when it is combined with Tolvaptan.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mannitol.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mannitol.
TrazodoneThe serum concentration of Mannitol can be decreased when it is combined with Trazodone.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mannitol.
TrifluoperazineThe serum concentration of Mannitol can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Mannitol can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Mannitol can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Mannitol can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Mannitol can be increased when it is combined with Troleandomycin.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.
VenlafaxineThe serum concentration of Mannitol can be increased when it is combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.
VinblastineThe serum concentration of Mannitol can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Mannitol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Mannitol can be increased when it is combined with Vinorelbine.
ZimelidineThe serum concentration of Mannitol can be increased when it is combined with Zimelidine.
Food InteractionsNot Available

Enzymes

Kind
Protein
Organism
Pseudomonas fluorescens
Pharmacological action
unknown
Actions
substrate
General Function:
Nucleotide binding
Specific Function:
Not Available
Gene Name:
mtlD
Uniprot ID:
O08355
Molecular Weight:
54497.41 Da
References
  1. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23